eravacycline dihydrochloride 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, protein-synthesis inhibitors, tetracycline derivatives 5294 1334714-66-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • eravacycline dihydrochloride
  • xerava
  • TP-434
Eravacycline is a fluorocycline antibacterial within the tetracycline class of antibacterial drugs. Eravacycline disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit thus preventing the incorporation of amino acid residues into elongating peptide chains.
  • Molecular weight: 558.56
  • Formula: C27H31FN4O8
  • CLOGP: 0.01
  • LIPINSKI: 3
  • HAC: 12
  • HDO: 6
  • TPSA: 193.73
  • ALOGS: -2.82
  • ROTB: 5
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 2.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.71 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.18 % Lombardo F, Berellini G, Obach RS
S (Water solubility) 50 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.455 Moderate 0.78
caco2-efflux Caco-2 efflux ratio (BA/AB) 5.333 Moderate 0.78
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 1.202 10^-6 cm/s Moderate 0.78
dh-clint Dog hepatocyte intrinsic clearance 3.069 uL/min/10^6 cells Moderate 0.78
dppb Dog plasma protein binding (% unbound) 52.420 % Moderate 0.78
fcs-ppb Fetal calf serum protein binding (% unbound) 41.840 % Moderate 0.78
herg hERG pIC50 4.509 pIC50 Moderate 0.78
hh-clint Human hepatocyte intrinsic clearance 1.754 uL/min/10^6 cells Moderate 0.78
hlm-clint Human liver microsomal intrinsic clearance 3.048 uL/min/mg protein Moderate 0.78
hppb Human plasma protein binding (% unbound) 41.390 % Moderate 0.78
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 67
kinase-selectivity-class AXL,BRAF,CDK4,CDK9,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K6,MAP3K14,MAPK7,MAPK8,STK33,TEK 14
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 7.295 Moderate 0.78
mh-clint Mouse hepatocyte intrinsic clearance 3.639 Moderate 0.78
mppb Mouse plasma protein binding (% unbound) 43.080 Moderate 0.78
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 5.984 Moderate 0.78
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 58.660 % Moderate 0.78
rh-clint Rat hepatocyte intrinsic clearance 1.592 uL/min/10^6 cells Moderate 0.78
rh-fuinc Rat hepatocyte fraction unbound in incubation 88.840 % Moderate 0.78
rppb Rat plasma protein binding (% unbound) 38.200 % Moderate 0.78
solubility-dd Solubility at pH 7.4 in DMSO 903.649 uM Moderate 0.78

Approvals:

DateAgencyCompanyOrphan
Aug. 27, 2018 FDA TETRAPHASE PHARMS
Sept. 20, 2018 EMA TETRAPHASE PHARMS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Infectious disease of abdomen indication 128070006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.13 acidic
pKa2 8.11 acidic
pKa3 10.06 acidic
pKa4 11.96 acidic
pKa5 12.87 acidic
pKa6 13.5 acidic
pKa7 9.56 Basic
pKa8 8.88 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 100MG BASE/VIAL XERAVA TETRAPHASE PHARMS N211109 June 3, 2020 RX POWDER INTRAVENOUS 8796245 Aug. 7, 2029 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER
EQ 50MG BASE/VIAL XERAVA TETRAPHASE PHARMS N211109 Aug. 27, 2018 RX POWDER INTRAVENOUS 8796245 Aug. 7, 2029 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 100MG BASE/VIAL XERAVA TETRAPHASE PHARMS N211109 June 3, 2020 RX POWDER INTRAVENOUS Aug. 27, 2023 NEW CHEMICAL ENTITY
EQ 50MG BASE/VIAL XERAVA TETRAPHASE PHARMS N211109 Aug. 27, 2018 RX POWDER INTRAVENOUS Aug. 27, 2023 NEW CHEMICAL ENTITY
EQ 100MG BASE/VIAL XERAVA TETRAPHASE PHARMS N211109 June 3, 2020 RX POWDER INTRAVENOUS Aug. 27, 2028 GENERATING ANTIBIOTIC INCENTIVES NOW
EQ 50MG BASE/VIAL XERAVA TETRAPHASE PHARMS N211109 Aug. 27, 2018 RX POWDER INTRAVENOUS Aug. 27, 2028 GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

None

External reference:

IDSource
WK1NMH89VJ UNII
C4723361 UMLSCUI
CHEBI:754900 CHEBI
CHEMBL2219414 ChEMBL_ID
56951485 PUBCHEM_CID
CHEMBL1951095 ChEMBL_ID
D10369 KEGG_DRUG
C571179 MESH_SUPPLEMENTAL_RECORD_UI
DB12329 DRUGBANK_ID
288715 MMSL
34818 MMSL
017696 NDDF
2055907 RXNORM
WK1NMH89VJ INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Xerava HUMAN PRESCRIPTION DRUG LABEL 1 71773-050 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS NDA 31 sections
Xerava HUMAN PRESCRIPTION DRUG LABEL 1 71773-100 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS NDA 31 sections